Cargando…

Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria

Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulos...

Descripción completa

Detalles Bibliográficos
Autores principales: Russom, Mulugeta, Fitsum, Yodit, Debesai, Merhawi, Russom, Natnael, Bahta, Merhawi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848631/
https://www.ncbi.nlm.nih.gov/pubmed/35170870
http://dx.doi.org/10.1002/prp2.934
_version_ 1784652293582356480
author Russom, Mulugeta
Fitsum, Yodit
Debesai, Merhawi
Russom, Natnael
Bahta, Merhawi
author_facet Russom, Mulugeta
Fitsum, Yodit
Debesai, Merhawi
Russom, Natnael
Bahta, Merhawi
author_sort Russom, Mulugeta
collection PubMed
description Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulosin and priapism is causal. All currently available evidence such as experimental, biological, toxicological, published studies, and safety data mined from the WHO global pharmacovigilance database was systematically organized into the Austin Bradford Hill causality assessment framework. In the international pharmacovigilance database, a strong association between tamsulosin and priapism (IC(025) = 4.1; PRR(025) = 19.9; ROR(025) = 20) was observed. There were 122 cases of priapism associated with tamsulosin submitted to the database from 23 countries. In 87.7% of the cases, tamsulosin was reported as a ‘sole suspect,’ and in 50.8%, it was the only drug administered. In several patients, priapism resolved following discontinuation of tamsulosin and recurred after its reintroduction. Both in the published and unpublished data, for majority of the cases, the time to onset of priapism was within few days following the first intake of tamsulosin. Cases of priapism, particularly those published, were consistent in their clinical features with patients experiencing prolonged painful erection that required aspiration of cavernosal blood, irrigation of the corpora cavernosa, and treatment with vasopressors. Other alpha‐adrenergic blocking agents that are structurally analogous with tamsulosin have also been associated with priapism. In several cases, tamsulosin was used off‐label, for the treatment of ureteral calculi expulsion. Eight patients experienced priapism that ended up with serious complications such as ejaculation disorders and erectile dysfunction. The currently available totality of evidence suggests that the association of tamsulosin and priapism is causal. Healthcare professionals are therefore recommended to cautiously prescribe tamsulosin and ensure that consumers are aware of the potential risk of priapism.
format Online
Article
Text
id pubmed-8848631
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88486312022-02-25 Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria Russom, Mulugeta Fitsum, Yodit Debesai, Merhawi Russom, Natnael Bahta, Merhawi Pharmacol Res Perspect Original Articles Tamsulosin hydrochloride, a selective alpha‐adrenergic blocking agent has been previously associated with priapism. Priapism is a medically serious condition that, if not intervened, can cause permanent erectile dysfunction. This study was conducted to investigate whether the association of tamsulosin and priapism is causal. All currently available evidence such as experimental, biological, toxicological, published studies, and safety data mined from the WHO global pharmacovigilance database was systematically organized into the Austin Bradford Hill causality assessment framework. In the international pharmacovigilance database, a strong association between tamsulosin and priapism (IC(025) = 4.1; PRR(025) = 19.9; ROR(025) = 20) was observed. There were 122 cases of priapism associated with tamsulosin submitted to the database from 23 countries. In 87.7% of the cases, tamsulosin was reported as a ‘sole suspect,’ and in 50.8%, it was the only drug administered. In several patients, priapism resolved following discontinuation of tamsulosin and recurred after its reintroduction. Both in the published and unpublished data, for majority of the cases, the time to onset of priapism was within few days following the first intake of tamsulosin. Cases of priapism, particularly those published, were consistent in their clinical features with patients experiencing prolonged painful erection that required aspiration of cavernosal blood, irrigation of the corpora cavernosa, and treatment with vasopressors. Other alpha‐adrenergic blocking agents that are structurally analogous with tamsulosin have also been associated with priapism. In several cases, tamsulosin was used off‐label, for the treatment of ureteral calculi expulsion. Eight patients experienced priapism that ended up with serious complications such as ejaculation disorders and erectile dysfunction. The currently available totality of evidence suggests that the association of tamsulosin and priapism is causal. Healthcare professionals are therefore recommended to cautiously prescribe tamsulosin and ensure that consumers are aware of the potential risk of priapism. John Wiley and Sons Inc. 2022-02-16 /pmc/articles/PMC8848631/ /pubmed/35170870 http://dx.doi.org/10.1002/prp2.934 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Russom, Mulugeta
Fitsum, Yodit
Debesai, Merhawi
Russom, Natnael
Bahta, Merhawi
Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title_full Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title_fullStr Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title_full_unstemmed Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title_short Tamsulosin and risk of priapism: A causality assessment using Austin Bradford Hill Criteria
title_sort tamsulosin and risk of priapism: a causality assessment using austin bradford hill criteria
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848631/
https://www.ncbi.nlm.nih.gov/pubmed/35170870
http://dx.doi.org/10.1002/prp2.934
work_keys_str_mv AT russommulugeta tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria
AT fitsumyodit tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria
AT debesaimerhawi tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria
AT russomnatnael tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria
AT bahtamerhawi tamsulosinandriskofpriapismacausalityassessmentusingaustinbradfordhillcriteria